Alessandra Fabi, Elizabeth M Gavioli, Renuka Wakade, Maria C Spera, Santiago Miracle, Neus Valveny, Elizabeth Butler, Maria DePizzol, Pier Adelchi Ruffini, Marcello Allegretti
{"title":"接受单药紫杉类药物化疗的转移性乳腺癌患者的疲劳：真实世界数据全球网络。","authors":"Alessandra Fabi, Elizabeth M Gavioli, Renuka Wakade, Maria C Spera, Santiago Miracle, Neus Valveny, Elizabeth Butler, Maria DePizzol, Pier Adelchi Ruffini, Marcello Allegretti","doi":"10.1177/17588359241240972","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cancer-related fatigue (CRF) occurs in nearly all patients with metastatic breast cancer (MBC).</p><p><strong>Objectives: </strong>This real-world analysis aimed to describe the prevalence and importance of fatigue in patients with MBC within 3 months of treatment with single-agent taxane-based chemotherapy during the timeframe of 2020-2022 in the United States and Europe. It was also conducted to assess whether there was a difference in relapsed patients compared to patients diagnosed <i>de novo</i>.</p><p><strong>Design: </strong>Electronic health records were analyzed from approximately 150 million patients to identify patients with MBC who underwent taxane treatment.</p><p><strong>Results: </strong>In 2021, 50,490 patients had MBC, of whom 16,170 were diagnosed <i>de novo</i> and 34,330 experienced relapse. The proportion of patients undergoing taxane-based chemotherapy was 7.5% (<i>n</i> = 1220) and 13.4% (<i>n</i> = 4590), respectively, and the prevalence of any fatigue and CRF was similar between the groups (24.6% <i>versus</i> 25.7% and 6.6% <i>versus</i> 5.4%, respectively).</p><p><strong>Conclusion: </strong>At least one in four patients with MBC undergoing taxane-based treatment will experience fatigue. This highlights the importance of validating screening tools to identify CRF, which is necessary to advance clinical trials aimed at investigating treatment strategies to improve patient-centered outcomes for fatigue.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241240972"},"PeriodicalIF":4.3000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282541/pdf/","citationCount":"0","resultStr":"{\"title\":\"Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global network.\",\"authors\":\"Alessandra Fabi, Elizabeth M Gavioli, Renuka Wakade, Maria C Spera, Santiago Miracle, Neus Valveny, Elizabeth Butler, Maria DePizzol, Pier Adelchi Ruffini, Marcello Allegretti\",\"doi\":\"10.1177/17588359241240972\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cancer-related fatigue (CRF) occurs in nearly all patients with metastatic breast cancer (MBC).</p><p><strong>Objectives: </strong>This real-world analysis aimed to describe the prevalence and importance of fatigue in patients with MBC within 3 months of treatment with single-agent taxane-based chemotherapy during the timeframe of 2020-2022 in the United States and Europe. It was also conducted to assess whether there was a difference in relapsed patients compared to patients diagnosed <i>de novo</i>.</p><p><strong>Design: </strong>Electronic health records were analyzed from approximately 150 million patients to identify patients with MBC who underwent taxane treatment.</p><p><strong>Results: </strong>In 2021, 50,490 patients had MBC, of whom 16,170 were diagnosed <i>de novo</i> and 34,330 experienced relapse. The proportion of patients undergoing taxane-based chemotherapy was 7.5% (<i>n</i> = 1220) and 13.4% (<i>n</i> = 4590), respectively, and the prevalence of any fatigue and CRF was similar between the groups (24.6% <i>versus</i> 25.7% and 6.6% <i>versus</i> 5.4%, respectively).</p><p><strong>Conclusion: </strong>At least one in four patients with MBC undergoing taxane-based treatment will experience fatigue. This highlights the importance of validating screening tools to identify CRF, which is necessary to advance clinical trials aimed at investigating treatment strategies to improve patient-centered outcomes for fatigue.</p>\",\"PeriodicalId\":23053,\"journal\":{\"name\":\"Therapeutic Advances in Medical Oncology\",\"volume\":\"16 \",\"pages\":\"17588359241240972\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282541/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17588359241240972\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359241240972","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global network.
Background: Cancer-related fatigue (CRF) occurs in nearly all patients with metastatic breast cancer (MBC).
Objectives: This real-world analysis aimed to describe the prevalence and importance of fatigue in patients with MBC within 3 months of treatment with single-agent taxane-based chemotherapy during the timeframe of 2020-2022 in the United States and Europe. It was also conducted to assess whether there was a difference in relapsed patients compared to patients diagnosed de novo.
Design: Electronic health records were analyzed from approximately 150 million patients to identify patients with MBC who underwent taxane treatment.
Results: In 2021, 50,490 patients had MBC, of whom 16,170 were diagnosed de novo and 34,330 experienced relapse. The proportion of patients undergoing taxane-based chemotherapy was 7.5% (n = 1220) and 13.4% (n = 4590), respectively, and the prevalence of any fatigue and CRF was similar between the groups (24.6% versus 25.7% and 6.6% versus 5.4%, respectively).
Conclusion: At least one in four patients with MBC undergoing taxane-based treatment will experience fatigue. This highlights the importance of validating screening tools to identify CRF, which is necessary to advance clinical trials aimed at investigating treatment strategies to improve patient-centered outcomes for fatigue.
期刊介绍：
Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
